Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)
Others
Ratios

BioNexus Gene Lab (BGLC) EBIT (2018 - 2025)

Historic EBIT for BioNexus Gene Lab (BGLC) over the last 8 years, with Q3 2025 value amounting to -$702509.0.

  • BioNexus Gene Lab's EBIT rose 4748.08% to -$702509.0 in Q3 2025 from the same period last year, while for Sep 2025 it was -$2.3 million, marking a year-over-year decrease of 16101.67%. This contributed to the annual value of -$1.6 million for FY2024, which is 3932.34% up from last year.
  • Latest data reveals that BioNexus Gene Lab reported EBIT of -$702509.0 as of Q3 2025, which was up 4748.08% from -$611293.0 recorded in Q2 2025.
  • BioNexus Gene Lab's EBIT's 5-year high stood at $372641.0 during Q3 2021, with a 5-year trough of -$2.5 million in Q3 2023.
  • For the 5-year period, BioNexus Gene Lab's EBIT averaged around -$280783.7, with its median value being -$79028.0 (2024).
  • In the last 5 years, BioNexus Gene Lab's EBIT skyrocketed by 671391.45% in 2021 and then plummeted by 377719.39% in 2023.
  • BioNexus Gene Lab's EBIT (Quarter) stood at $201063.0 in 2021, then plummeted by 161.02% to -$122689.0 in 2022, then skyrocketed by 310.09% to $257754.0 in 2023, then crashed by 261.48% to -$416220.0 in 2024, then plummeted by 68.78% to -$702509.0 in 2025.
  • Its EBIT was -$702509.0 in Q3 2025, compared to -$611293.0 in Q2 2025 and -$618418.0 in Q1 2025.